**Ablynx Secures $2 Million in Funding to Propel Nanobody Development Programs**
Ablynx, a pioneering Sanofi company based in Ghent, Belgium, has announced a successful raise of $2 million aimed at further advancing its groundbreaking Nanobody® therapeutic programs. These proprietary proteins, derived from single-domain antibody fragments, blend the strengths of traditional antibody therapies with the advantages of small-molecule drugs, offering a novel approach to treating some of the world’s most serious and life-threatening diseases. With applications spanning across critical medical fields such as inflammation, hematology, immuno-oncology, and oncology, Ablynx is firmly positioned at the cutting edge of therapeutic innovation. The recent funding will enable the company to bolster its research and development initiatives, focusing on the acceleration of its Nanobody pipelines that promise to transform treatment methodologies. Since its acquisition by Sanofi in June 2018, Ablynx has benefited from the larger organization’s commitment to fostering breakthrough innovations aimed at addressing multiple disease targets simultaneously through multi-specific molecules. The $2 million funding will enhance Ablynx's capabilities in scaling its Nanobody development, streamlining clinical trials, and expanding its portfolio to meet pressing medical needs. As the healthcare landscape continues to evolve, Ablynx remains dedicated to delivering impactful solutions for patients, showcasing the significant potential of Nanobodies to improve therapeutic outcomes across a variety of disease states. This latest funding round is a testament to the confidence in Ablynx’s unique technology and its critical role within Sanofi’s broader mission to advance healthcare innovation.
